drugset / Trial / NCT06364787
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Phase 1
Not yet recruiting
18 enrolled
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd. · collabChinese Academy of Medical Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in first-line treatment of patients with hepatocellular carcinoma.
Timeline
- Start
- 2024-04-26
- Primary completion
- 2026-04-26
- Completion
- 2026-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | γδ T cells | Cell therapy | 1e+08 cells/kg | Other |
| Subject | γδ T cells | Cell therapy | 2e+08 cells/kg | Other |
| Subject | γδ T cells | Cell therapy | 4e+08 cells/kg | Other |